This feature examines the impact of pharmacologic interventions on the treatment of the critically ill patient–an area of health care that has become increasingly complex. It will review recent advances (including evolving and controversial data) in drug therapy for adult ICU patients and assess these new modalities in terms of clinical, humanistic, and economic outcomes. Direct questions or comments to Gil Fraser, PharmD, at fraseg@mmc.org.
Get full access to this article
View all access options for this article.
References
1.
Anonymous.Guidelines 2000 for cardiopulmonary resuscitation and emergency cardiovascular care. An international consensus on science. Circulation.2000; 102(suppl I): I-1–I-378.
2.
LandryD.W., OliverJ.A.The pathogenesis of vasodilatory shock. N Engl J Med.2001; 345: 588–95.
3.
Practice parameters for hemodynamic support of sepsis in adult patients in sepsis.Task Force of the American College of Critical Care Medicine, Society of Critical Care Medicine. Crit Care Med.1999; 27: 639–60.
4.
ParrilloJ.E., ParkerM.M., NatansonC.Septic shock in humans. Advances in the understanding of pathogenesis, cardiovascular dysfunction, and therapy. Ann Intern Med.1990; 113: 227–42.
5.
ParrilloJ.E.Pathogenetic mechanisms of septic shock. N Engl J Med.1993; 328: 1471–7.
6.
BernardG.R., VincentJ.L., LaterreP.F.Efficacy and safety of recombinant human activated protein C for severe sepsis. N Engl J Med.2001; 344: 699–709.
7.
VervloetM.G., ThijsL.G., HackC.E.Derangements of coagulation and fibrinolysis in critically ill patients with sepsis and septic shock. Semin Thromb Hemost.1998; 24: 33–44.
8.
MoralesD.L., GreggD., HelmanD.N.Arginine vasopressin in the treatment of 50 patients with postcardiotomy vasodilatory shock. Ann Thorac Surg.2000; 69: 102–6.
9.
ChenJ.M., CullinaneS., SpanierT.B.Vasopressin deficiency and pressor hypersensitivity in hemodynamically unstable organ donors. Circulation.1999; 100(suppl II): II244–6.
10.
GoldJ.A., CullinaneS., ChenJ.Vasopressin as an alternative to norepinephrine in the treatment of milrinone-induced hypotension. Crit Care Med.2000; 28: 249–52.
11.
ChernowB., RothB.L.Pharmacologic manipulation of the peripheral vasculature in shock: Clinical and experimental approaches. Circ Shock.1986; 18: 141–55.
12.
AngusD.C., Linde-ZwirbleW.T., LidickerJ.Epidemiology of severe sepsis in the United States: Analysis of incidence, outcome, and associated costs of care. Crit Care Med.2001; 29: 1303–10.
13.
HolmesC.L., PatelB.M., RussellJ.A.Physiology of vasopressin relevant to management of septic shock. Chest.2001; 120: 989–1002.
14.
AlbrightT.N., ZimmermanM.A., SelzmanC.H.Vasopressin in the cardiac surgery intensive care unit. Am J Crit Care.2002; 11: 326–32.
15.
SharsharT., CarlierR., BlanchardA.Depletion of neurohypophyseal content of vasopressin in septic shock. Crit Care Med.2002; 30; 497–500.
16.
ReidI.A.Role of vasopressin deficiency in the vasodilation of septic shock. Circulation.1997; 95: 1108–10.
17.
ForrestP.Vasopressin and shock. Anaesth Intensive Care.2001; 29: 463–72.
18.
VincentJ.L.Endocrine support in the critically ill. Crit Care Med.2002; 30: 702–3.
19.
ArgenzianoM., ChoudhriA.F., OzM.C.A prospective randomized trial of arginine vasopressin in the treatment of vasodilatory shock after left ventricular assist device placement. Circulation.1997; 96(suppl II): II-286–90.
20.
ArgenzianoM., ChenJ.M., ChoudhriA.F.Management of vasodilatory shock after cardiac surgery: Identification of predisposing factors and use of a novel pressor agent. J Thorac Cardiovasc Surg.1998; 116: 973–80.
21.
ArgenzianoM., ChenJ.M., CullinaneS.Arginine vasopressin in the management of vasodilatory hypotension after cardiac transplantation. J Heart Lung Transplant.1999; 18: 814–7.
22.
RosenzweigE.B., StarcT.J., ChenJ.M.Intravenous arginine-vasopressin in children with vasodilatory shock after cardiac surgery. Circulation.1999; 100(suppl II): II182–6.
23.
LandryD.W., LevinH.R., GallantE.M.Vasopressin pressor hypersensitivity in vasodilatory septic shock. Crit Care Med.1997; 25: 1279–82.
24.
LandryD.W., LevinH.R., GallantE.M.Vasopressin deficiency contributes to the vasodilation of septic shock. Circulation.1997; 95: 1122–5.
25.
MalayM.B., AshtonR.C.Jr., LandryD.W.Low-dose vasopressin in the treatment of vasodilatory septic shock. J Trauma.1999; 47: 699–703.
26.
TsuneyoshiI., YamadaH., KakihanaY.Hemodynamic and metabolic effects of low-dose vasopressin infusions in vasodilatory septic shock. Crit Care Med.2001; 29: 487–93.
27.
HolmesC.L., WalleyK.R., ChittockD.R.The effects of vasopressin on hemodynamics and renal function in severe septic shock: A case series. Intensive Care Med.2001; 27: 1416–21.
28.
DunserM.W., MayrA.J., UlmerH.The effects of vasopressin on systemic hemodynamics in catecholamine-resistant septic and postcardiotomy shock: A retrospective analysis. Anesth Analg.2001; 93: 7–13.
29.
HolmesC.L., WalleyK.R., RussellJ.A.Vasopressin and cardiac performance [letter]. Chest.2002; 121: 1724.
30.
JacksonW.L., ShorrA.F.Vasopressin and cardiac performance [letter]. Chest.2002; 121: 1723.
31.
DunserM.W., MayrA.J., StallingerA.Cardiac performance during vasopressin infusion in postcardiotomy shock. Intensive Care Med.2002; 28: 746–51.
32.
KahnJ.M., KressJ.P., HallJ.B.Skin necrosis after extravasation of low-dose vasopressin administered for septic shock. Crit Care Med.2002; 30: 1899–901.
